Medtronic, a Dublin-based medical device company with offices in Littleton, announced Monday it is moving forward with a renal denervation trial after a previous study yielded positive results.
According to Medtronic, renal denervation is a minimally-invasive procedure designed to reduce hypertension during which a catheter emits a radio frequency across multiple electrodes. That energy is delivered to a renal artery to disrupt nerves.
A previous three-month study found that the first 80 patients saw “statistically significant and clinically important blood pressure reductions” in patients treated with renal denervation, according to a press release.
Blood pressure of patients in the study who underwent renal denervation saw their blood pressure decline an average of 10 mm Hg.
